CRIS Current Research Information System

CASTELLUCCI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.721
AS - Asia 9.263
EU - Europa 6.927
AF - Africa 621
SA - Sud America 488
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 28.029
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.567
VN - Vietnam 2.774
SG - Singapore 2.380
CN - Cina 2.149
GB - Regno Unito 1.794
IT - Italia 968
DE - Germania 965
SE - Svezia 858
HK - Hong Kong 647
FR - Francia 469
IN - India 414
RU - Federazione Russa 392
BR - Brasile 337
UA - Ucraina 332
IE - Irlanda 278
FI - Finlandia 175
ZA - Sudafrica 160
NL - Olanda 156
TG - Togo 154
CI - Costa d'Avorio 143
KR - Corea 143
BD - Bangladesh 142
JP - Giappone 136
EE - Estonia 122
CH - Svizzera 115
CA - Canada 105
JO - Giordania 104
BG - Bulgaria 81
SC - Seychelles 69
AR - Argentina 67
PH - Filippine 55
NG - Nigeria 47
PL - Polonia 42
TH - Thailandia 42
ID - Indonesia 41
BE - Belgio 38
IQ - Iraq 36
TR - Turchia 35
AT - Austria 32
ES - Italia 32
IR - Iran 32
TW - Taiwan 26
MX - Messico 25
EC - Ecuador 20
SA - Arabia Saudita 16
PK - Pakistan 15
HR - Croazia 14
CL - Cile 13
CO - Colombia 12
VE - Venezuela 12
CZ - Repubblica Ceca 11
LT - Lituania 11
MY - Malesia 11
UZ - Uzbekistan 11
MA - Marocco 9
PY - Paraguay 9
GR - Grecia 8
PE - Perù 8
RO - Romania 8
TN - Tunisia 8
LB - Libano 7
EG - Egitto 6
KZ - Kazakistan 6
MN - Mongolia 6
SK - Slovacchia (Repubblica Slovacca) 6
BO - Bolivia 5
CR - Costa Rica 5
ET - Etiopia 5
JM - Giamaica 5
NP - Nepal 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
AU - Australia 4
AZ - Azerbaigian 4
CY - Cipro 4
HU - Ungheria 4
PT - Portogallo 4
BJ - Benin 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KE - Kenya 3
LY - Libia 3
MU - Mauritius 3
PS - Palestinian Territory 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BY - Bielorussia 2
DK - Danimarca 2
IL - Israele 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NO - Norvegia 2
OM - Oman 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BB - Barbados 1
BN - Brunei Darussalam 1
Totale 28.010
Salva come PNG Salva come JPEG
Città #
Singapore 1.665
Southend 1.575
Ashburn 1.303
Fairfield 934
Chandler 899
Hong Kong 609
San Jose 512
Houston 455
Wilmington 451
Santa Clara 433
Woodbridge 431
Ho Chi Minh City 426
Seattle 413
Hanoi 400
Cambridge 346
Princeton 341
Beijing 301
Ann Arbor 279
Dublin 277
Hefei 255
Dong Ket 234
Boardman 230
Jacksonville 214
Los Angeles 177
Bologna 167
Lauterbourg 161
Helsinki 159
New York 155
Lomé 154
Westminster 150
Abidjan 143
Padova 131
Nanjing 127
Munich 121
Berlin 112
Tokyo 111
Seoul 110
Amman 102
Bern 100
Dallas 100
Council Bluffs 90
Jinan 84
Da Nang 79
Shenyang 76
Sofia 74
Saint Petersburg 71
Buffalo 70
Turin 69
Milan 66
São Paulo 64
Changsha 63
Florence 63
Frankfurt am Main 60
Redondo Beach 60
Haiphong 58
Guangzhou 55
Hebei 52
Bremen 48
Mülheim 47
Tianjin 47
San Diego 45
Abeokuta 44
Redmond 44
Shanghai 42
Nanchang 41
Medford 39
Jiaxing 38
Brussels 37
Zhengzhou 36
Chicago 35
Johannesburg 34
Phoenix 34
Redwood City 34
Toronto 34
The Dalles 32
Orem 29
London 28
Nuremberg 28
Falkenstein 27
Brooklyn 26
Bengaluru 25
Dearborn 25
Des Moines 25
Norwalk 24
Atlanta 23
Biên Hòa 23
Hangzhou 23
Montreal 23
Warsaw 23
Yubileyny 22
Baghdad 21
Hải Dương 21
Mahé 21
Tongling 21
Jakarta 19
Taiyuan 19
Amsterdam 18
Haikou 18
Kuban 18
Wuhan 18
Totale 17.696
Salva come PNG Salva come JPEG
Nome #
Combined (18)F-FDG-PET/CT Imaging in Radiotherapy Target Delineation for Head-and-Neck Cancer. 439
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? 345
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study 319
18F-FDG PET early after radiotherapy in lymphoma patients. 319
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 311
11-C-choline PET/CT imaging for localization of recurrent prostate cancer 294
A case of [68Ga]Ga-FAPI-46-avid and [18F]F-FDG-negative COVID-19 pneumonia sequelae 270
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 265
11 C-CHOLINE-PET/CT FOR PREOPERATIVE N-STAGING IN HIGH RISK PROSTATE CANCER 263
Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. 238
Molecular modelling evaluation of exon 18 His845_Asn848delinsPro pDGFRα mutation in a metastatic GIST patient responding to imatinib 237
11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. 234
11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. 233
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. 229
Identification of PET/CT radiomic signature for classification of locally recurrent rectal cancer: A network-based feature selection approach 226
(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. 225
11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. 225
Prediction Nomogram for 68 Ga-PSMA-11 PET/CT in Different Clinical Settings of PSA Failure After Radical Treatment for Prostate Cancer 225
11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard 224
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 218
Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (case reports). 213
Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study 212
11C-CHOLINE PET/TC imaging for localization of recurrent prostate cancer 212
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 210
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 210
11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. 209
Pathological and molecular diagnosis of bilateral inguinal lymph nodes metastases from low-grade endometrial adenocarcinoma: a case report with review of the literature 205
11C-Choline PET/CT for Restaging of Bladder Cancer 205
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. 204
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. 204
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 203
Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study 202
18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin 201
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 200
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. 200
CT with 11C-Choline for identification of recurrent prostate cancer 197
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 197
Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high-risk prostate cancer: potential implications for PSMA-PET patient selection 195
18f-fdg pet/ct for restaging gastric cancer after surgical resection 195
EFFETTO DELLA TERAPIA ORMONALE SULLA CAPTAZIONE DI 11-C-COLINA IN PAZIENTI CON RIPRESA DI MALATTIA DA CARCINOMA PROSTATICO 191
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 191
11C-Choline PET/CT in hormonal resistant patients after radical prostatectomy 191
Comparison between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. 190
11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. 189
PET-TC con 11C-colina e Spettroscopia di Risonanza Magnetica nella diagnosi e localizzazione del tumore prostatico: confronto con l'analisi seriata dello specimen chirurgico. 189
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 188
Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer 187
Potential Prognostic Role of 18F-FDG PET/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study 186
18 FDG-PET nel follow.up dei pazienti con carcinoma tiroideo differenziato 185
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 185
Incidental detection of basaloid thymic carcinoma with 68 Ga-PSMA-11 PET/CT in recurrent prostate cancer patient 183
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. 182
18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. 180
CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report 178
(68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer 176
Image fusione between PET and CT for radiotherapy treatment planning for head and neck cancer 174
Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. 174
TOMOGRAFIA AD EMISSIONE DI POSITRONI CON 11-C-COLINA INTEGRATO A UN SISTEMA TC (11-C-CHOLINE-PET/TC) E RISONANZA MAGNETICA DI SPETTROSCOPIA DEL PROTONE (1-H-MRSI) NELLA DIAGNOSI DI NEOPLASIA PROSTATICA: STUDIO COMPARATIVO 174
[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy. 172
Erratum to: Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. 172
Evaluation of unusual neuroendocrine tumours by means of (68)Ga-DOTA-NOC PET. 171
11C-methionine vs. 18F-FDG PET in soft tissue sarcoma patients treated with neoadjuvant therapy: preliminary results 170
Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of 68Ga-PSMA-11 in Patients with Prostate Cancer. 170
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 168
11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. 167
Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis 166
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. 165
Restaging Clear Cell Renal Carcinoma With 18F-FDG PET/CT. 165
Sextant localization of prostate cancer with 11-C-choline PET/CT: comparison with three-dimensional proton MR spectroscopic imaging using step section histopathology as standard of references 164
18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. 164
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 164
11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. 164
Response Evaluation to Radium-223-Dichloride in Castration-Resistant Metastatic Prostate Cancer using 11C-choline PET/CT and Bone Scintigraphy 163
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. 163
Current Application and Future Perspectives of Prostate Specific Membrane Antigen PET Imaging in Prostate Cancer 163
Sextant localization of prostate cancer:comparison between Magnetic Resonance Spectroscopic Imaging and 11C-Choline PET-CT. 162
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. 162
High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results. 162
The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. 160
(18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. 160
Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20 ng/mL. 159
Incidental finding of [68Ga]Ga-PSMA-avid intraductal papillary mucinous neoplasm 159
Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial 159
State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer 158
Pictorial essay: normal variants, lesions, and pitfalls in Ga-68-PSMA PET imaging of prostate cancer. 158
POSITRON-EMISSION TOMOGRAPHY IN IMAGING AND STAGING PROSTATE CANCER 157
C–CHOLINE PET/CT IMAGING IS USEFUL FOR METASTATIC LYMPH NODES DETECTION IN NEWLY DIAGNOSED PROSTATE CANCER 156
Incidental finding of an (11)C-choline PET-positive solitary plasmacytoma lesion. 156
C–CHOLINE PET/CT IMAGING IS USEFUL FOR METASTATIC LYMPH NODES DETECTION IN NEWLY DIAGNOSED PROSTATE CANCER 155
PET/TC CON 11-C-COLINA E SPETTROSCOPIA DO RISONANZA MAGNETICA NELLA DIAGNOSI E LOCALIZZAZIONE DEL TUMORE PROSTATICO: CONFRONTO CON LA ANALISI SERIATA DELLO SPICIMEN CHIRURGICO 154
Role of (11)C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy 154
Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial 154
Management of patients with gastrointestinal stromal tumor in clinical practice in Italy: a critical "event tree model" analysis of decision-making processes and outcomes. 154
Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer 153
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 153
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series 152
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 151
Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database 151
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? 149
Sextant localization of prostate cancer with 11-C-choline PET/CT: comparison with three-dimensional proton MR spectroscopic imaging using step section histopathology as standard of references 148
Totale 19.433
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.503
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.503
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021616 0 0 0 0 0 0 0 0 0 0 0 616
2021/20223.598 892 89 188 295 286 139 57 193 100 181 701 477
2022/20233.781 361 546 232 477 237 293 98 202 695 128 302 210
2023/20241.129 95 165 31 68 72 220 57 262 50 56 26 27
2024/20253.838 167 561 284 278 666 248 300 132 95 212 157 738
2025/20268.461 650 728 707 565 1.009 467 821 227 1.852 768 378 289
Totale 28.503